{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:22:46Z","timestamp":1787847766325,"version":"build-2784847793"},"reference-count":60,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Ovarian cancer (OC) is among the most prevalent malignant tumors of the female reproductive system. Its high mortality rate is strongly associated with the development of chemotherapy resistance, making research into resistance mechanisms critical for improving patient outcomes. In recent years, ferroptosis, an iron-dependent form of cell death, has garnered significant attention in tumor resistance research due to its unique regulatory mechanisms. Studies indicate that ferroptosis contributes to OC resistance by modulating pathways including lipid peroxidation, iron metabolism, and antioxidant systems; however, its precise molecular mechanisms remain incompletely elucidated. Furthermore, the interaction between ferroptosis and resistance to conventional chemotherapy agents in OC has emerged as a research hotspot. This systematic review examines the fundamental characteristics of ferroptosis and its potential mechanisms in OC resistance, while exploring therapeutic strategies targeting ferroptosis-related pathways to reverse drug resistance. By synthesizing existing research advances, this paper aims to provide new theoretical foundations to deepen our understanding of OC resistance mechanisms and to suggest potential directions for developing novel targeted therapeutic approaches.<\/jats:p>","DOI":"10.4103\/jcrt.jcrt_454_25","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T07:00:10Z","timestamp":1779951610000},"page":"241-247","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Ferroptosis in ovarian cancer drug resistance: A literature review ovarian cancer"],"prefix":"10.4103","volume":"22","author":[{"given":"Fatao","family":"Guo","sequence":"first","affiliation":[{"name":"School of Clinical Medicine, Shandong Second Medical University, Weifang, China"},{"name":"Department of Obstetrics and Gynecology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxin","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China"},{"name":"Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenwei","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueyuan","family":"Miao","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China"},{"name":"Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingchun","family":"Ma","sequence":"additional","affiliation":[{"name":"School of Clinical Medicine, Shandong Second Medical University, Weifang, China"},{"name":"Department of Obstetrics and Gynecology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"R1-20260528","doi-asserted-by":"crossref","first-page":"851","DOI":"10.4103\/jcrt.jcrt_28_25","article-title":"Development and validation of a risk signature based on disulidptosis-related ferroptosis genes in ovarian cancer","volume":"21","author":"Sun","year":"2025","journal-title":"J Cancer Res Ther"},{"key":"R2-20260528","doi-asserted-by":"crossref","first-page":"869","DOI":"10.4103\/jcrt.jcrt_656_21","article-title":"MRI assessment of ovarian masses and correlating with CA-125","volume":"20","author":"Ranganath","year":"2024","journal-title":"J Cancer Res Ther"},{"key":"R3-20260528","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.4103\/jcrt.JCRT_480_19","article-title":"CXCR4 and RIF1 overexpression induces resistance of epithelial ovarian cancer to cisplatin-based chemotherapy","volume":"17","author":"Sad","year":"2021","journal-title":"J Cancer Res Ther"},{"key":"R4-20260528","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrc2167","article-title":"The resurgence of platinum-based cancer chemotherapy","volume":"7","author":"Kelland","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"R5-20260528","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1124\/pr.111.005637","article-title":"Cisplatin resistance: A cellular selfdefence mechanism resulting from multiple epigenetic and genetic changes","volume":"64","author":"Shen","year":"2012","journal-title":"Pharmacol Rev"},{"key":"R6-20260528","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1039\/D2MO00220E","article-title":"A study of the molecular mechanisms of cisplatin resistance based on a multi-omics approach","volume":"19","author":"Yue","year":"2023","journal-title":"Mol Omics"},{"key":"R7-20260528","doi-asserted-by":"crossref","first-page":"122720","DOI":"10.1016\/j.lfs.2024.122720","article-title":"Targeting ferroptosis in ovarian cancer: Novel strategies to overcome chemotherapy resistance","volume":"349","author":"Kapper","year":"2024","journal-title":"Life Sci"},{"key":"R8-20260528","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.4103\/jcrt.jcrt_806_23","article-title":"Pseudolaric acid B triggers ferritinophagy and ferroptosis via upregulating NCOA4 in lung adenocarcinoma cells","volume":"19","author":"Miao","year":"2023","journal-title":"J Cancer Res Ther"},{"key":"R9-20260528","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.tcb.2015.10.014","article-title":"Ferroptosis: Death by lipid peroxidation","volume":"26","author":"Yang","year":"2016","journal-title":"Trends Cell Biol"},{"key":"R10-20260528","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/s41419-023-05930-w","article-title":"Ferroptosis as a potential target for cancer therapy","volume":"14","author":"Chen","year":"2023","journal-title":"Cell Death Dis"},{"key":"R11-20260528","doi-asserted-by":"crossref","first-page":"879317","DOI":"10.3389\/fphar.2022.879317","article-title":"Ferroptosis and tumor drug resistance: Current status and major challenges","volume":"13","author":"Nie","year":"2022","journal-title":"Front Pharmacol"},{"key":"R12-20260528","doi-asserted-by":"crossref","first-page":"100916","DOI":"10.1016\/j.drup.2022.100916","article-title":"Overcoming cancer chemotherapy resistance by the induction of ferroptosis","volume":"66","author":"Wang","year":"2023","journal-title":"Drug Resist Updat"},{"key":"R13-20260528","doi-asserted-by":"crossref","first-page":"992","DOI":"10.3389\/fphar.2017.00992","article-title":"The role of ferroptosis in cancer development and treatment response","volume":"8","author":"Lu","year":"2018","journal-title":"Front Pharmacol"},{"key":"R14-20260528","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00018-023-04907-4","article-title":"Ferroptosis and EMT: Key targets for combating cancer progression and therapy resistance","volume":"80","author":"Ren","year":"2023","journal-title":"Cell Mol Life Sci"},{"key":"R15-20260528","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40364-020-00229-w","article-title":"Novel insights on targeting ferroptosis in cancer therapy","volume":"8","author":"Zuo","year":"2020","journal-title":"Biomark Res"},{"key":"R16-20260528","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41392-020-00216-5","article-title":"Ferroptosis and lipid interactions metabolism","volume":"5","author":"Dingshan","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"R17-20260528","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41422-019-0164-5","article-title":"The molecular machinery of regulated cell death","volume":"29","author":"Tang","year":"2019","journal-title":"Cell Res"},{"key":"R18-20260528","doi-asserted-by":"crossref","first-page":"e1904197","DOI":"10.1002\/adma.201904197","article-title":"Recent progress in ferroptosis inducers for cancer therapy","volume":"31","author":"Liang","year":"2019","journal-title":"Adv Mater"},{"key":"R19-20260528","doi-asserted-by":"crossref","first-page":"119486","DOI":"10.1016\/j.biomaterials.2019.119486","article-title":"Triggered ferroptotic polymer micelles for reversing multidrug resistance to chemotherapy","volume":"223","author":"Gao","year":"2019","journal-title":"Biomaterials"},{"key":"R20-20260528","doi-asserted-by":"crossref","first-page":"430939","DOI":"10.1155\/2010\/430939","article-title":"Role of glutathione in the regulation of cisplatin resistance in cancer chemotherapy","volume":"2010","author":"Chen","year":"2010","journal-title":"Met Based Drugs"},{"key":"R21-20260528","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1021\/acs.jproteome.9b00209","article-title":"Integration of metabolomics and transcriptomics to reveal metabolic characteristics and key targets associated with cisplatin resistance in non-mall cell lung cancer","volume":"18","author":"Shi","year":"2019","journal-title":"J Proteome Res"},{"key":"R22-20260528","doi-asserted-by":"crossref","first-page":"6766","DOI":"10.3390\/molecules26226766","article-title":"1H HR-MAS NMR based metabolic profiling of lung cancer cells with induced and deinduced cisplatin resistance to reveal metabolic resistance adaptations","volume":"26","author":"Vermathen","year":"2021","journal-title":"Molecules"},{"key":"R23-20260528","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s12885-021-07879-5","article-title":"Reprogramming of glutamine metabolism via glutamine synthetase silencing induces cisplatin resistance in A2780 ovarian cancer cells","volume":"21","author":"Guo","year":"2021","journal-title":"BMC Cancer"},{"key":"R24-20260528","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13048-015-0140-8","article-title":"Ametabolomic approach to identifying platinum resistance in ovarian cancer, J","volume":"8","author":"Poisson","year":"2015","journal-title":"Ovarian Res"},{"key":"R25-20260528","first-page":"e98597","article-title":"Metabolic vulnerability of cisplatinresistant cancers","volume":"3","author":"Obrist","year":"2018","journal-title":"EMBO J."},{"key":"R26-20260528","doi-asserted-by":"crossref","first-page":"e517","DOI":"10.1002\/ctm2.517","article-title":"Glutathione peroxidase 4-dependent glutathione highconsumption drives acquired platinum chemoresistance in lung cancer-derived brain metastasis","volume":"11","author":"Liu","year":"2021","journal-title":"Clin Transl Med"},{"key":"R27-20260528","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1126\/science.1196333","article-title":"Frequent mutations in the chromatin remodelling gene ARID1A in ovarian clear cell carcinoma","volume":"330","author":"Jones","year":"2010","journal-title":"Science"},{"key":"R28-20260528","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ccell.2018.12.009","article-title":"Targeting the vulnerability of glutathione metabolism in ARID1A-deficient cancers","volume":"35","author":"Ogiwara","year":"2019","journal-title":"Cancer Cell"},{"key":"R29-20260528","doi-asserted-by":"crossref","first-page":"681223","DOI":"10.3389\/fphar.2021.681223","article-title":"Lidocaine promoted ferroptosis by targeting miR-382-5p\/SLC7A11 axis in ovarian and breast cancer","volume":"12","author":"Sun","year":"2021","journal-title":"Front Pharmacol"},{"key":"R30-20260528","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3892\/ijo.2024.5664","article-title":"ARID1A restrains EMT and stemness of ovarian cancer cells through the Hippo pathway","volume":"65","author":"Xu","year":"2024","journal-title":"Int J Oncol"},{"key":"R31-20260528","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.ccell.2023.03.002","article-title":"Targeting the mevalonate pathway suppresses ARID1A-inactivated cancers by promoting pyroptosis","volume":"41","author":"Zhou","year":"2023","journal-title":"Cancer Cell"},{"key":"R32-20260528","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1007\/s12672-025-03051-8","article-title":"Nuclear receptor subfamily 1 group D member 2 induces chemoresistance in ovarian cancer by regulating ferroptosis and immune infiltration","volume":"16","author":"Wang","year":"2025","journal-title":"Discov Oncol"},{"key":"R33-20260528","doi-asserted-by":"crossref","first-page":"1675373","DOI":"10.3389\/fimmu.2025.1675373","article-title":"Knockdown of TOP2A reverses cisplatin resistance in ovarian cancer by inhibiting EMT via ferroptosis mediated by the TP53\/GPX4\/SLC7A11 axis","volume":"16","author":"Liu","year":"2025","journal-title":"Front Immunol"},{"key":"R34-20260528","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ygyno.2021.07.005","article-title":"ARID1A mutation\/ARID1A loss is associated with a high immunogenic profile in clear cell ovarian cancer","volume":"162","author":"Kuroda","year":"2021","journal-title":"Gynecol Oncol"},{"key":"R35-20260528","doi-asserted-by":"crossref","first-page":"101928","DOI":"10.1016\/j.redox.2021.101928","article-title":"PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient ovarian cancer","volume":"42","author":"Hong","year":"2021","journal-title":"Redox Biol"},{"key":"R36-20260528","doi-asserted-by":"crossref","first-page":"103350","DOI":"10.1016\/j.redox.2024.103350","article-title":"Targeting GPX4-mediated ferroptosis protection sensitizes BRCA1-deficient cancer cells to PARP inhibitors","volume":"76","author":"Xie","year":"2024","journal-title":"Redox Biol"},{"key":"R37-20260528","doi-asserted-by":"crossref","first-page":"184","DOI":"10.5483\/BMBRep.2022-0175","article-title":"circRNA circSnx12 confers Cisplatin chemoresistance to ovarian cancer by inhibiting ferroptosis through a miR-194-5p\/SLC7A11 axis","volume":"56","author":"Qin","year":"2023","journal-title":"BMB Rep"},{"key":"R38-20260528","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1158\/0008-5472.CAN-20-1488","article-title":"Frizzled-7 identifies platinum-tolerant ovarian cancer cells susceptible to ferroptosis","volume":"81","author":"Wang","year":"2021","journal-title":"Cancer Res"},{"key":"R39-20260528","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1158\/0008-5472.CAN-22-1159","article-title":"MEX3A mediates p53 degradation to suppress ferroptosis and facilitate ovarian cancer tumorigenesis","volume":"83","author":"Wang","year":"2023","journal-title":"Cancer Res"},{"key":"R40-20260528","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41416-019-0660-x","article-title":"Activation of the reverse transsulfuration pathway through NRF2\/CBS confers erastin-induced ferroptosis resistance","volume":"122","author":"Liu","year":"2020","journal-title":"Br J Cancer"},{"key":"R41-20260528","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.3389\/fonc.2019.01398","article-title":"Erastin reverses ABCB1-mediated docetaxel resistance in ovarian cancer","volume":"9","author":"Zhou","year":"2019","journal-title":"Front Oncol"},{"key":"R42-20260528","doi-asserted-by":"crossref","first-page":"109422","DOI":"10.1016\/j.intimp.2022.109422","article-title":"Erastin enhances metastatic potential of ferroptosis-resistant ovarian cancer cells by M2 polarization through STAT3\/IL-8 axis","volume":"113","author":"Cang","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"R43-20260528","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1158\/1541-7786.MCR-19-0691","article-title":"A TAZ-ANGPTL4-NOX2 axis regulates ferroptotic cell death and chemoresistance in epithelial ovarian cancer","volume":"18","author":"Yang","year":"2020","journal-title":"Mol Cancer Res"},{"key":"R44-20260528","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/1097-0134(20000901)40:4<590::AID-PROT50>3.0.CO;2-P","article-title":"Adrenodoxin: Structure, stability, and electron transfer properties","volume":"40","author":"Grinberg","year":"2000","journal-title":"Proteins"},{"key":"R45-20260528","doi-asserted-by":"crossref","first-page":"11775","DOI":"10.1073\/pnas.1004250107","article-title":"Humans possess two mitochondrial ferredoxins, Fdx1 and Fdx2, with distinct roles in steroidogenesis, heme, and Fe\/S cluster biosynthesis","volume":"107","author":"Sheftel","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R46-20260528","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.bbamcr.2011.11.002","article-title":"Both human ferredoxins 1 and 2 and ferredoxin reductase are important for iron-sulfur cluster biogenesis","volume":"1823","author":"Shi","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"R47-20260528","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3892\/or.2023.8561","article-title":"Ferredoxin1 expression in cisplatin-resistant ovarian cancer cells renders them resistant to cisplatin-induced ferroptosis","volume":"49","author":"Takahashi","year":"2023","journal-title":"Oncol Rep"},{"key":"R48-20260528","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2174\/0929867328666210810115812","article-title":"Ferroptosis: A trusted ally in combating drug resistance in cancer","volume":"29","author":"Ozkan","year":"2022","journal-title":"Curr Med Chem"},{"key":"R49-20260528","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.canlet.2016.07.035","article-title":"Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer","volume":"381","author":"Roh","year":"2016","journal-title":"Cancer Lett"},{"key":"R50-20260528","doi-asserted-by":"crossref","first-page":"154701","DOI":"10.1016\/j.phymed.2023.154701","article-title":"Shikonin and cisplatin synergistically overcome cisplatin resistance of ovarian cancer by inducing ferroptosis via upregulation of HMOX1 to promote Fe2+accumulation","volume":"112","author":"Ni","year":"2023","journal-title":"Phytomedicine"},{"key":"R51-20260528","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s12013-023-01212-6","article-title":"Curcumin and ferroptosis: A promising target for disease prevention and treatment","volume":"82","author":"Foroutan","year":"2024","journal-title":"Cell Biochem Biophys"},{"key":"R52-20260528","doi-asserted-by":"crossref","first-page":"e0261370","DOI":"10.1371\/journal.pone.0261370","article-title":"Curcumin suppresses tumorigenesis by ferroptosis in breast cancer","volume":"17","author":"Cao","year":"2022","journal-title":"PLoS One"},{"key":"R53-20260528","doi-asserted-by":"crossref","first-page":"110791","DOI":"10.1016\/j.cellsig.2023.110791","article-title":"Curcumin derivative NL01 induces ferroptosis in ovarian cancer cells via HCAR1\/MCT1 signaling","volume":"109","author":"Shi","year":"2023","journal-title":"Cell Signal"},{"key":"R54-20260528","first-page":"1","article-title":"A novel curcumin derivative CUR3d induces ferroptosis in ovarian cancer cells via targeting GPX4","volume":"520","author":"Wang","year":"2021","journal-title":"Cancer Letters,"},{"key":"R55-20260528","first-page":"6","article-title":"The curcuminoid EF24 targets nuclear factor-kB and iron metabolism in human pancreatic cancer cells","volume":"25","author":"Gong","year":"2022","journal-title":"Molecular Med Rep"},{"key":"R56-20260528","first-page":"1019632","article-title":"EF24, a novel curcumin analog, interacts with microtubules and causes ROS generation and ferroptosis in ovarian cancer cells","volume":"12","author":"Jiang","year":"2022","journal-title":"Front Oncol"},{"key":"R57-20260528","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41422-019-0263-3","article-title":"The role of ferroptosis in ionizing radiation-induced cell death and tumor suppression","volume":"30","author":"Lei","year":"2020","journal-title":"Cell Res"},{"key":"R58-20260528","doi-asserted-by":"crossref","first-page":"6532","DOI":"10.3390\/ijms22126532","article-title":"Ovarian cancer immunotherapy and personalized medicine","volume":"22","author":"Morand","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R59-20260528","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1038\/onc.2017.11","article-title":"Iron addiction: A novel therapeutic target in ovarian cancer","volume":"36","author":"Basuli","year":"2017","journal-title":"Oncogene"},{"key":"R60-20260528","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2147\/IJN.S282489","article-title":"p53 promoted ferroptosis in ovarian cancer cells treated with human serum incubated-superparamagnetic iron oxides","volume":"16","author":"Zhang","year":"2021","journal-title":"Int J Nanomedicine"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_454_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:36:49Z","timestamp":1787845009000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_454_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_454_25","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"2025-03-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}